1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"Neuroscience Consortium" is currently closed and not accepting applications.
Neuroscience Consortium is sponsored by Massachusetts Life Sciences Center (MLSC). This program funds pre-clinical research focused on understanding Alzheimer's and neurodegenerative diseases at Massachusetts research institutions.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Neuroscience Consortium - MLSC The Neuroscience Consortium funds pre-clinical neuroscience research at Massachusetts academic and research institutions. The MLSC in collaboration with Alzheimer Disease Research Center at Massachusetts General Hospital brings together company partners with researchers focused on understanding Alzheimer’s and neurodegenerative diseases to further research and collaboration in the space.
Companies that have participated in the Consortium include AbbVie, Biogen, Celgene, General Electric, Lundbeck, Merck, Novartis, and Sunovion Pharmaceuticals (Consortium Members). Nearly $10 million has been committed by consortium members to fund research through this program. The consortium thrives off both commitments from biotech companies and applications for innovative translational research.
Every year Consortium Members pool their resources to fund the identification and validation of novel targets for the symptomatic treatment and modification of these chronic and debilitating neurological diseases. It is required all proposals be anchored in recognized human disease genetics and pathophysiology, or within pathways of known relevance to human disease, and should be translational, rather than exploratory.
Examples of such proposals might include research that: Confirms or refutes the involvement of a particular pathway or mechanism in human disease; Identifies new molecular targets, or strengthens the case for a potential target, or rules out a suspected target; Establishes new and improved animal models of human disease in the identified focus areas, with established face and/or construct validity; Develops a method for manipulating or measuring a pathway of known human pathological relevance; or Identifies or validates a biomarker than can be used for drug discovery and/or development.
Applications for the current round of funding will be open from May 18, 2026 to Aug. 31, 2026. Please submit your application using this link .
Companies that are interested in becoming a Consortium Members should contact MLSC staff to discuss further. Please contact neuroscience@masslifesciences. com .
Launched in 2013, the consortium originally adopted a broad interest in neurological diseases with a focus on neurodegenerative and neuroinflammatory diseases. Following multiple rounds of proposals, a collective focus on Alzheimer’s Disease emerged and now the consortium spends its time and effort on understanding and developing novel solutions for AD.
Since inception, the program has garnered nearly $10 million in industry commitments and funded the work of more than 40 Principal Investigators in Massachusetts. Through the work of this program, public resources for neuroscience and Alzheimer’s researchers have been generated.
More information on these resources can be found here: Alzheimer DataLENS provides information on hypothesis-driven and data driven research, allowing neuroscientists to share, browse and visualize comprehensive results from bioinformatics analysis of public omics datasets. It also serves as a tool to organize and share results from MassCATS investigations.
Our team is happy to discuss either joining the consortium as a company Consortium Member or applying as a Massachusetts-based researcher. To connect with MLSC staff, please contact neuroscience@masslifesciences. com .
Ernest E. Just Life Sciences Initiative Business Builds: Life Sciences
According to the current listing, eligibility includes: Massachusetts research institutions. Confirm the full requirements in the official notice before applying.
The published deadline was August 31, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Neuroscience Consortium is funded by Massachusetts Life Sciences Center (MLSC). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Massachusetts. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleAwards slashed by half, life sciences applicants rejected at 95%, and the White House steering which fields get funded. How the GRFP went from funding the person to funding the priority.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read article